BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Phase 1 Recruiting 20 enrolled iCell Gene Therapeutics iCell ImmunityX（Hangzhou）Co., Ltd. · collab

NaSequentialOpen-labelTreatment

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.

Timeline

Start: 2024-08-31
Primary completion: 2026-08
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCMA-CD19 cCAR T cells	Cell therapy	—	Intravenous

Indications

No indication recorded.